Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $13.38

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given a consensus recommendation of "Buy" by the nine ratings firms that are currently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $13.38.

Several equities analysts recently weighed in on the stock. Jefferies Financial Group lifted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. Guggenheim restated a "buy" rating on shares of Compass Therapeutics in a research note on Tuesday, April 22nd. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Monday. Finally, Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st.

Insider Buying and Selling at Compass Therapeutics

In related news, insider Jonathan Anderman bought 20,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently made changes to their positions in CMPX. MPM Bioimpact LLC boosted its holdings in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the period. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at about $11,293,000. Tang Capital Management LLC grew its position in shares of Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after buying an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP grew its position in shares of Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after buying an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP raised its stake in Compass Therapeutics by 2.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after acquiring an additional 75,000 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Trading Down 2.2 %

NASDAQ:CMPX traded down $0.04 on Friday, hitting $1.82. 503,249 shares of the stock were exchanged, compared to its average volume of 881,638. The stock has a market cap of $251.68 million, a PE ratio of -4.92 and a beta of 1.40. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The stock has a fifty day moving average of $2.12 and a 200-day moving average of $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). As a group, analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.